Keeping It in the Family: HER3 as a Target in Brain Metastases-Reference-Cited by-同舟云学术

Keeping It in the Family: HER3 as a Target in Brain Metastases

Published:2023-06-12 Issue:16 Volume:29 Page:2961-2963
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Kabraji Sheheryar¹²³^ORCID,Lin Nancy U.¹²³^ORCID

Affiliation:

1. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

2. 2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.

3. 3Harvard Medical School, Boston, Massachusetts.

Abstract

SummaryIn 180 patients with metastatic breast cancer and non–small cell lung cancer (NSCLC), HER3 expression was found in >70% of brain metastases (BM). HER3-targeting antibody–drug conjugates have demonstrated efficacy in HER3-expressing metastatic breast cancer and NSCLC. Thus, HER3 expression by IHC may be a biomarker for development of HER3-targeting BM-specific therapeutics.See related article by Tomasich et al., p. 3225

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-1107/3339857/ccr-23-1107.pdf

Reference24 articles.

1. Frequent overexpression of HER3 in brain metastases from breast and lung cancer;Tomasich;Clin Cancer Res,2023

2. Thirty years of HER3: from basic biology to therapeutic interventions;Haikala;Clin Cancer Res,2021

3. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer;Da Silva;Breast Cancer Res,2010

4. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors;Sun;Clin Cancer Res,2009

5. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients;Scharpenseel;Sci Rep,2019